Supplemental Content 2: Table: Individual and Group SLAH Treatment Summaries									
Patient	Side treated	Stereotactic platform	Laser treatment zones (number)	Laser treatment time (min)*	Length of hippocampus ablated (cm)	Ablation volume (cm^3)	Proportion of structure(s) ablated (%)		
							Hippocampus	Amygdala	AHC
1	Right	CRW	3	8.6	3.07	5.30	59	4	50
	Right	CRW	3	10.9	2.72	4.92	67**	66**	69**
2	Right	CRW	2	9.7	1.55	6.32	49	77	60
3	Left	CRW	2	4.4	2.86	3.93	86	12	51
4	Left	CRW	3	6.7	2.48	5.94	72	49	59
5	Left	CRW	2	5.4	2.44	5.43	55	67	61
6	Left	CRW	3	3.4	2.40	3.52	62	41	52
7	Right	CRW	2	5.1	1.97	4.74	54	40	49
8	Left	CPSF	3	7.4	2.15	4.03	63	46	53
9	Left	CPSF	2	4.4	2.94	6.85	66	71	68
10	Right	CRW	5	13.2	2.79	6.22	70	86	73
11	Left	CPSF	3	7.7	2.12	5.32	54	29	46
12	Right	CPSF	3	9.6	n/a	4.22	n/a	n/a	n/a
13	Left	CPSF	5	26.1	2.74	7.59	55	83	66
	Left	CRW	5	21.5	3.00	5.82	69**	88**	76**
Group data	6 Right: 9 Left	CRW 10 procedures in 9 patients: CPSF 5 procedures in 5 patients	3.1 +/- 1.2 (mean +/- S.D.)	9.6 +/- 6.4	2.5 +/- 0.44	5.3 +/- 1.1	63 +/- 10	54 +/- 27	60 +/- 9.7

Ablation length and volumes estimates were generated post hoc from manually segmented volumetric T1 post contrast sequence MRI obtained immediately following treatment and compared to preoperative manually segmented structures. *Laser therapy almost exclusively performed at power = 12 Watt; **Proportion of structure ablated represents total calculated volume achieved following both SLAH procedures; CRW, Cosman-Roberts-Wells rigid frame (Integra, Inc.); CPSF, ClearPoint SmartFrame MRI-guided trajectory frame (MRI Interventions, Inc.); n/a, data not available; S.D., standard deviation of the mean; AHC, amygdalohippocampal complex.